Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

(1) On 28 June 2022, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004, by which funds managed by Clayton, Dubilier & Rice, LLC (“CD&R”), registered in Delaware, U.S., intend to acquire joint control over Covetrus, Inc. (the “Covetrus”), headquartered in Portland, Maine, U.S., together with TPG Partners VIII, L.P., registered in Delaware and TPG Healthcare Partners, L.P., registered in Delaware (funds ultimately managed by TPG, Inc (“TPG”)) by way of a purchase of the entire outstanding share capital of Covetrus.

(2) The business activities of the undertakings concerned are:

(a) CD&R is a private equity investment firm, based in the USA, which originates, structures and frequently acts as lead equity investor in management buyouts, strategic minority equity investments and other strategic investments.

(b) TPG is a leading global alternative asset management firm founded in San Francisco with $113.6 billion of assets under management as at 31 December, 2021.

(c) Covetrus is a globally active provider of animal-health technology and services to companies supporting the companion, equine and large animal veterinary markets, specifically veterinarians and animal health practitioners.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.